Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tumors with L858R were associated with a lower CTR (p=0.046), and tended to have a higher incidence of a lepidic growth pattern by pathological evaluation (p=0.073) compared to those with Del-19.
|
28577949 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 50 lung cancer patients' tumor tissues were analyzed, and two frequent mutations associated with therapeutic efficiency of lung cancer were identified, including deletion of exon 19 (8/50) and L858R point mutation in exon 21 (12/50).
|
22901298 |
2012 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
A total of 72 patients were enrolled in this study, of which 62 patients (86.1%) had EGFR-mutant tumors (34 patients with exon 19 deletions, and 28 patients with L858R).
|
25514801 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Afatinib is 1 of 3 tyrosine kinase inhibitors approved in the United States for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions (del19) or exon 21 (L858R) substitution mutations.
|
29799327 |
2018 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
After the detection limits were determined, we examined DNA isolated from lung cancer specimens and circulating plasma DNA samples of 39 adenocarcinoma patients whose primary tumors harbored EGFR exon 19 deletions or L858R.
|
22858585 |
2012 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
As the L858R mutation within exon 21 of the EGFR gene was identified in the middle-lobe tumor and the subcarinal node but not in the upper-lobe tumor, we diagnosed as double primary cancers.
|
20307913 |
2010 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
AS-PCR analysis of treatment-naïve tumor samples revealed somatic T790M mutation in 3/394 (1%) non-small cell lung carcinomas (NSCLC) carrying the tyrosine kinase inhibitor (TKI)-sensitizing EGFR mutation, but in none of 334 NSCLC lacking EGFR exon 19 deletions (ex19del) or L858R substitutions and in none of 235 non-lung tumors.
|
30145586 |
2018 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
By mass spectrometry genotyping, the plasma samples contained mutant DNA corresponding to 5/14 EGFR Exon 19 deletions and 3/4 EGFR L858R mutations previously diagnosed in the matched tumors.
|
21130517 |
2011 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
CHMFL-EGFR-26 bore acceptable pharmacokinetic properties and demonstrated dose-dependent tumor growth suppression in the H1975 (EGFR L858R/T790M) and PC-9 (EGFR del19) inoculated xenograft mouse models.
|
28407693 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Circulating tumor DNA (ctDNA) is released into the circulation by tumor cell turnover and has been shown to be detectable in urine.<b>Experimental Design:</b> We tested the hypothesis that dynamic changes in EGFR activating (exon 19del and L858R) and resistance (T790M) mutation levels detected in urine could inform tumor response within days of therapy for advanced non-small cell lung cancer (NSCLC) patients receiving osimertinib, a second-line third-generation anti-EGFR tyrosine kinase inhibitor.<b>Results:</b> Eight of nine evaluable NSCLC patients had detectable T790M-mutant DNA fragments in pretreatment baseline samples.
|
28420725 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Classic somatic EGFR kinase domain mutations (such as L858R and exon 19 deletions) make tumors addicted to their signaling cascades and generate a therapeutic window for the use of ATP-mimetic EGFR TKIs.
|
25296354 |
2014 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared with tumor tissue samples, the sensitivity and specificity of ddPCR were 76.19% (16/21) and 96.55% (28/29) for mutant L858R, and 88.89% (8/9) and 100% (41/41) for ex19del, respectively.
|
28789464 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Consequently, 12 available tumor specimens (five specimens for delE746-A750 and seven specimens for L858R) with both factors were evaluated.
|
23645738 |
2013 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
During the cancer development, sequential DNA sequencing data that used circulating cell-free tumor DNA, and NGS revealed EGFR L858R and T790M mutations, MYC amplification, and other gene variations.
|
30572427 |
2018 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutation status was retrospectively determined for 76 patients, 52 (68.4%) of whom had EGFR-mutated tumors (exon 19 deletions in 26 and L858R point mutation in 24).
|
26725183 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR mutations were detected in tumor tissues from 27 of 49 NSCLC patients of Han ethnic group , with a positive rate of 55.1%; 19 of them had exon 19 deletions, seven (7) had L858R point mutations in exon 21 of EGFR and one (1) had mutations in both exon 18 G719X and exon 20 T790M of EGFR.
|
23803047 |
2013 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
EGFR T790M mutation, which conveys resistance to in the present study, [<sup>18</sup> F]FEWZ was assessed in vitro to determine efficacy relative to the starting compound and in vivo to measure the biodistribution and specificity of binding to EGFR wild-type, L858R and T790M bearing tumours.
|
31132309 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Eighteen out of 20 large cell carcinomas, not otherwise specified, had glandular differentiation upon immunohistochemistry, with an exon 21 L858R EGFR mutation in one (5 %) tumor, an exon 2 KRAS mutation in eight (40 %) tumors, and an ALK translocation in one (5 %) tumor, whereas two tumors positive for CK7 and CK5/6 and negative for all other markers were considered adenocarcinoma.
|
24221342 |
2014 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expert consensus has defined minimum requirements for routine testing and identification of epidermal growth factor (EGFR) mutations (15% of tumors harbor EGFR exon 19 deletions or exon 21 L858R substitutions) and anaplastic lymphoma kinase (ALK) rearrangements (5% of tumors) in advanced lung adenocarcinomas (ACs).
|
26620497 |
2016 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Finally, on PET imaging study using [<sup>18</sup>F]APP-1 with tumor-bearing mice, the H3255 tumor (L858R mutant) was more clearly visualized than the H1975 tumor (L858R/T790M mutant).
|
28435529 |
2017 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Finally, we evaluated the concordance between plasma and tumour tissues by simultaneously detecting EGFR L858R by ddPCR and LNA-dPNA PCR clamp in 132 tissues and matched plasma samples from patients with NSCLC.
|
30663747 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
For tumors with exon 19 deletions, the benefit was 50% greater (HR, 0.24; 95% CI, 0.20 to 0.29) than for tumors with exon 21 L858R substitution (HR, 0.48; 95% CI, 0.39 to 0.58; Pinteraction < .001).
|
25897154 |
2015 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report a case of emergent <i>MET</i> amplification detected in a tumor sample from a patient with NSCLC harboring EGFR L858R mutation after disease progression on erlotinib.
|
30881166 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here we report efficacy and safety data of an Asian subset of the phase III FLAURA trial (NCT02296125), which compares osimertinib with standard of care (SoC) EGFR tyrosine kinase inhibitors (TKIs) in patients with previously untreated advanced NSCLC with tumors harboring exon 19 deletion (Ex19del)/L858R EGFR TKI-sensitizing mutations.
|
30240852 |
2019 |
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we show that haploinsufficiency of Nkx2-1 in combination with oncogenic Kras(G12D), but not with oncogenic EGFR(L858R), caused pulmonary tumors in transgenic mice that were phenotypically similar to human mucinous adenocarcinomas.
|
23143308 |
2012 |